Compare ACRE & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACRE | PROF |
|---|---|---|
| Founded | 2011 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 252.4M | 263.8M |
| IPO Year | 2011 | 2017 |
| Metric | ACRE | PROF |
|---|---|---|
| Price | $4.88 | $7.41 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $5.38 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 512.9K | 115.0K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 11.58% | N/A |
| EPS Growth | ★ 26.17 | 25.89 |
| EPS | ★ 1.35 | N/A |
| Revenue | ★ $54,833,000.00 | $16,098,000.00 |
| Revenue This Year | N/A | $92.40 |
| Revenue Next Year | $16.28 | $64.10 |
| P/E Ratio | $3.61 | ★ N/A |
| Revenue Growth | N/A | ★ 50.73 |
| 52 Week Low | $4.14 | $3.92 |
| 52 Week High | $5.89 | $8.95 |
| Indicator | ACRE | PROF |
|---|---|---|
| Relative Strength Index (RSI) | 57.12 | 63.67 |
| Support Level | $4.67 | $6.47 |
| Resistance Level | $5.06 | $8.95 |
| Average True Range (ATR) | 0.14 | 0.48 |
| MACD | 0.03 | 0.10 |
| Stochastic Oscillator | 81.43 | 70.13 |
Ares Commercial Real Estate Corp is a specialty finance company and a real estate investment trust mainly engaged in originating and investing in commercial real estate (CRE) loans and related investments. It operates in one segment, namely originating and managing a diversified portfolio of CRE debt-related investments. The company recognizes the majority of its revenues in the form of interest income, which it receives from loans.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.